Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | AIP | O00170 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6683840 | 0.95 | LMNA (0.48) | LMNAKDM4EMCL1POLBHDAC3 | |
| SCHEMBL28107168 | 0.92 | LMNA (0.46) | LMNAKDM4EHDAC3HDAC1HDAC2 | |
| SCHEMBL30416681 | 0.92 | LMNA (0.46) | LMNAKDM4EHDAC3HDAC1HDAC2 | |
| SCHEMBL30068381 | 0.92 | LMNA (0.46) | LMNAKDM4EHDAC3HDAC1HDAC2 | |
| SCHEMBL30416186 | 0.92 | LMNA (0.46) | LMNAKDM4EHDAC3HDAC1HDAC2 | |
| SCHEMBL6682401 | 0.92 | LMNA (0.46) | LMNAKDM4EHDAC3HDAC1HDAC2 | |
| SCHEMBL30415482 | 0.92 | LMNA (0.46) | LMNAKDM4EHDAC3HDAC1HDAC2 | |
| SCHEMBL5909180 | 0.89 | LMNA (0.57) | LMNAKDM4EMCL1POLBTSHR | |
| SCHEMBL9456785 | 0.87 | TSHR (0.46) | LMNATSHRHDAC3HDAC1HDAC2 | |
| SCHEMBL1297846 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111205282-B | ER protein modulators and uses thereof | 上海科技大学 | 2023-12-01 | — | — | CN | claimed |
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| US-20260062580-A1 | REVERSIBLY THERMOCHROMIC COMPOSITION, REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT ENCAPSULATING REVERSIBLY THERMOCHROMIC COMPOSITION, AND WRITING INSTRUMENT USING REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT | THE PILOT INK CO., LTD. (JP) | 2026-03-05 | — | — | US | disclosed |
| US-12460099-B2 | Reversibly thermochromic composition, reversibly thermochromic microcapsule pigment encapsulating reversibly thermochromic composition, and writing instrument using reversibly thermochromic microcapsule pigment | THE PILOT INK CO., LTD. (JP) | 2025-11-04 | — | — | US | disclosed |
| EP-3608386-B1 | REVERSIBLY THERMOCHROMIC COMPOSITION, AND REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT HAVING SAME ENCLOSED THEREIN | PILOT INK CO LTD (JP) | 2025-02-19 | — | — | EP | disclosed |
| US-12123107-B2 | Reversibly thermochromic composite fiber | KABUSHIKI KAISHA PILOT CORPORATION (JP) | 2024-10-22 | — | — | US | disclosed |
| CN-111205282-B | ER protein modulators and uses thereof | 上海科技大学 | 2023-12-01 | — | — | CN | disclosed |
| CN-115996927-A | Pyrimido [5,4-d ] pyrimidine derivatives and combinations with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-04-21 | — | — | CN | disclosed |
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| US-20220169919-A1 | REVERSIBLY THERMOCHROMIC COMPOSITION, REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT ENCAPSULATING REVERSIBLY THERMOCHROMIC COMPOSITION, AND WRITING INSTRUMENT USING REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT | THE PILOT INK CO., LTD. (JP) | 2022-06-02 | — | — | US | disclosed |
| EP-0908501-A1 | Reversible thermochromic composition | THE PILOT INK CO., LTD. (JP) | 1999-04-14 | — | — | EP | disclosed |
| EP-0901468-A1 | PREPARATION OF LACTAMS FROM ALIPHATIC $g(a),$g(v)-DINITRILES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-03-17 | — | — | EP | disclosed |
| US-5858736-A | CONTACTING DINITRILE IN AQUEOUS MIXTURE WITH ENZYME CATALYST HAVING ALIPHATIC NITRILASE ACTIVITY OR COMBINATION OF NITRILE HYDRATASE AND AMIDASE ACTIVITY, CONTACTING PRODUCT WITH HYDROGEN AND HYDROGENATION CATALYST TO PRODUCE LACTAM | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0873881-A1 | Reversible thermochromic compositions | The Pilot Ink CO., Ltd. (JP) | 1998-10-28 | — | — | EP | disclosed |
| US-5814508-A | TREATING A WHOLE CELL CATALYST TO SELECT FOR A REGIOSELECTIVE NITRILASE ACTIVITY OR A NITRILE HYDRATASE ACTIVITY; CATALYTIC CONVERSION OF ALPHA-OMEGA DINITRILES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-09-29 | — | — | US | disclosed |
| US-5728556-A | REGIOSELECTIVE NITRILE HYDRATASE CATALYSIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-03-17 | — | — | US | disclosed |
| WO-1997044318-A1 | PREPARATION OF LACTAMS FROM ALIPHATIC α,φ-DINITRILES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-11-27 | — | — | WO | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062580-A1 | REVERSIBLY THERMOCHROMIC COMPOSITION, REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT ENCAPSULATING REVERSIBLY THERMOCHROMIC COMPOSITION, AND WRITING INSTRUMENT USING REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT | TYR, SCO2, HBB | LMNA 1365/4885KDM4E 3963/4885MCL1 1670/4885 |
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | LMNA 601/4885KDM4E 3192/4885MCL1 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.